Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes - PubMed (original) (raw)
Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes
Anthony J Gill et al. Hum Pathol. 2010 Jun.
Abstract
Up to 30% of pheochromocytomas and paragangliomas are associated with germline RET, Von Hippel-Lindau (VHL), neurofibromatosis type I (NF1), and succinate dehydrogenase subunits (SDHB, SDHC, and SDHD) mutations. Genetic testing allows familial counseling and identifies subjects at high risk of malignancy (SDHB mutations) or significant multiorgan disease (RET, VHL, or NF1). However, conventional genetic testing for all loci is burdensome and costly. We performed immunohistochemistry for SDHB on 58 tumors with known SDH mutation status. We defined positive as granular cytoplasmic staining (a mitochondrial pattern), weak diffuse as a cytoplasmic blush lacking definite granularity, and negative as completely absent staining in the presence of an internal positive control. All 12 SDH mutated tumors (6 SDHB, 5 SDHD, and 1 SDHC) showed weak diffuse or negative staining. Nine of 10 tumors with known mutations of VHL, RET, or NF1 showed positive staining. One VHL associated tumor showed weak diffuse staining. Of 36 tumors without germline mutations, 34 showed positive staining. One paraganglioma with no known SDH mutation but clinical features suggesting familial disease was negative, and one showed weak diffuse staining. We also performed immunohistochemistry for SDHB on 143 consecutive unselected tumors of which 21 were weak diffuse or negative. As SDH mutations are virtually always germline, we conclude that approximately 15% of all pheochromocytomas or paragangliomas are associated with germline SDH mutation and that immunohistochemistry can be used to triage genetic testing. Completely absent staining is more commonly found with SDHB mutation, whereas weak diffuse staining often occurs with SDHD mutation.
Crown Copyright 2010. Published by Elsevier Inc. All rights reserved.
Similar articles
- Genetic analysis of mitochondrial complex II subunits SDHD, SDHB and SDHC in paraganglioma and phaeochromocytoma susceptibility.
Astuti D, Hart-Holden N, Latif F, Lalloo F, Black GC, Lim C, Moran A, Grossman AB, Hodgson SV, Freemont A, Ramsden R, Eng C, Evans DG, Maher ER. Astuti D, et al. Clin Endocrinol (Oxf). 2003 Dec;59(6):728-33. doi: 10.1046/j.1365-2265.2003.01914.x. Clin Endocrinol (Oxf). 2003. PMID: 14974914 - Mutation analysis of SDHB and SDHC: novel germline mutations in sporadic head and neck paraganglioma and familial paraganglioma and/or pheochromocytoma.
Bayley JP, van Minderhout I, Weiss MM, Jansen JC, Oomen PH, Menko FH, Pasini B, Ferrando B, Wong N, Alpert LC, Williams R, Blair E, Devilee P, Taschner PE. Bayley JP, et al. BMC Med Genet. 2006 Jan 11;7:1. doi: 10.1186/1471-2350-7-1. BMC Med Genet. 2006. PMID: 16405730 Free PMC article. - Gross SDHB deletions in patients with paraganglioma detected by multiplex PCR: a possible hot spot?
Cascón A, Montero-Conde C, Ruiz-Llorente S, Mercadillo F, Letón R, Rodríguez-Antona C, Martínez-Delgado B, Delgado M, Díez A, Rovira A, Díaz JA, Robledo M. Cascón A, et al. Genes Chromosomes Cancer. 2006 Mar;45(3):213-9. doi: 10.1002/gcc.20283. Genes Chromosomes Cancer. 2006. PMID: 16258955 - Succinate dehydrogenase (SDH) and mitochondrial driven neoplasia.
Gill AJ. Gill AJ. Pathology. 2012 Jun;44(4):285-92. doi: 10.1097/PAT.0b013e3283539932. Pathology. 2012. PMID: 22544211 Review. - Genetic testing in pheochromocytoma- and paraganglioma-associated syndromes.
Benn DE, Richardson AL, Marsh DJ, Robinson BG. Benn DE, et al. Ann N Y Acad Sci. 2006 Aug;1073:104-11. doi: 10.1196/annals.1353.011. Ann N Y Acad Sci. 2006. PMID: 17102077 Review.
Cited by
- Urinary Bladder Paragangliomas: Analysis of Succinate Dehydrogenase and Outcome.
Gupta S, Zhang J, Rivera M, Erickson LA. Gupta S, et al. Endocr Pathol. 2016 Sep;27(3):243-52. doi: 10.1007/s12022-016-9439-2. Endocr Pathol. 2016. PMID: 27262318 - Succinate dehydrogenase expression in breast cancer.
Kim S, Kim DH, Jung WH, Koo JS. Kim S, et al. Springerplus. 2013 Jul 3;2(1):299. doi: 10.1186/2193-1801-2-299. Print 2013 Dec. Springerplus. 2013. PMID: 23888270 Free PMC article. - Molecular and therapeutic advances in the diagnosis and management of malignant pheochromocytomas and paragangliomas.
Lowery AJ, Walsh S, McDermott EW, Prichard RS. Lowery AJ, et al. Oncologist. 2013;18(4):391-407. doi: 10.1634/theoncologist.2012-0410. Epub 2013 Apr 10. Oncologist. 2013. PMID: 23576482 Free PMC article. Review. - SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T).
Papathomas TG, Oudijk L, Persu A, Gill AJ, van Nederveen F, Tischler AS, Tissier F, Volante M, Matias-Guiu X, Smid M, Favier J, Rapizzi E, Libe R, Currás-Freixes M, Aydin S, Huynh T, Lichtenauer U, van Berkel A, Canu L, Domingues R, Clifton-Bligh RJ, Bialas M, Vikkula M, Baretton G, Papotti M, Nesi G, Badoual C, Pacak K, Eisenhofer G, Timmers HJ, Beuschlein F, Bertherat J, Mannelli M, Robledo M, Gimenez-Roqueplo AP, Dinjens WN, Korpershoek E, de Krijger RR. Papathomas TG, et al. Mod Pathol. 2015 Jun;28(6):807-21. doi: 10.1038/modpathol.2015.41. Epub 2015 Feb 27. Mod Pathol. 2015. PMID: 25720320 - Top 10 Histological Mimics of Neuroendocrine Carcinoma You Should Not Miss in the Head and Neck.
Juhlin CC, Bal M. Juhlin CC, et al. Head Neck Pathol. 2023 Mar;17(1):66-84. doi: 10.1007/s12105-022-01521-x. Epub 2023 Mar 20. Head Neck Pathol. 2023. PMID: 36941503 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous